NO20042373L - Nye 1,2,4-tiadiazoliumderivater som melanokortinreseptormodulatorer - Google Patents

Nye 1,2,4-tiadiazoliumderivater som melanokortinreseptormodulatorer

Info

Publication number
NO20042373L
NO20042373L NO20042373A NO20042373A NO20042373L NO 20042373 L NO20042373 L NO 20042373L NO 20042373 A NO20042373 A NO 20042373A NO 20042373 A NO20042373 A NO 20042373A NO 20042373 L NO20042373 L NO 20042373L
Authority
NO
Norway
Prior art keywords
new
receptor modulators
melanocortin receptor
thiadiazolium derivatives
thiadiazolium
Prior art date
Application number
NO20042373A
Other languages
English (en)
Other versions
NO328194B1 (no
Inventor
Allen B Reitz
Carlos R Plata-Salaman
Boyu Zhao
Kevin Pan
Virginia Smith-Swintosky
Magdalena Eisinger
Louis J Fitzpatrick
Daniel H Lee
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of NO20042373L publication Critical patent/NO20042373L/no
Publication of NO328194B1 publication Critical patent/NO328194B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4018—Esters of cycloaliphatic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
NO20042373A 2001-11-08 2004-06-07 Nye 1,2,4-tiadiazoliumderivater som melanokortinreseptormodulatorer NO328194B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33776201P 2001-11-08 2001-11-08
PCT/US2002/035365 WO2003040118A1 (en) 2001-11-08 2002-11-05 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators

Publications (2)

Publication Number Publication Date
NO20042373L true NO20042373L (no) 2004-06-07
NO328194B1 NO328194B1 (no) 2010-01-04

Family

ID=23321888

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042373A NO328194B1 (no) 2001-11-08 2004-06-07 Nye 1,2,4-tiadiazoliumderivater som melanokortinreseptormodulatorer

Country Status (25)

Country Link
US (4) US7319107B2 (no)
EP (1) EP1444215B1 (no)
JP (1) JP4491235B2 (no)
CN (1) CN100422164C (no)
AR (1) AR037284A1 (no)
AT (1) ATE333449T1 (no)
AU (1) AU2002340372B2 (no)
BR (1) BR0214023A (no)
CA (1) CA2466145A1 (no)
CY (1) CY1105233T1 (no)
DE (1) DE60213276T2 (no)
DK (1) DK1444215T3 (no)
ES (1) ES2268108T3 (no)
IL (2) IL161830A0 (no)
MX (1) MXPA04004457A (no)
MY (1) MY134994A (no)
NO (1) NO328194B1 (no)
NZ (1) NZ532884A (no)
PT (1) PT1444215E (no)
RS (1) RS51199B (no)
RU (1) RU2323932C2 (no)
SI (1) SI1444215T1 (no)
TW (1) TWI317358B (no)
WO (1) WO2003040118A1 (no)
ZA (1) ZA200404487B (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
WO2003013571A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7319107B2 (en) * 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
EP1446394B1 (en) * 2001-11-08 2006-11-02 Ortho-McNeil Pharmaceutical, Inc. Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US8460243B2 (en) * 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
AU2005216969A1 (en) * 2004-02-23 2005-09-09 Prolexys Pharmaceuticals Inc. Non-peptidyl agents with pHSP20-like activity, and uses thereof
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CA2572455C (en) 2004-06-04 2014-10-28 Therasense, Inc. Diabetes care host-client architecture and data management system
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US7981146B2 (en) * 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
US8083787B2 (en) * 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20090043365A1 (en) * 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US8007524B2 (en) * 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US8527313B2 (en) * 2006-05-15 2013-09-03 Sap Ag Document instantiation triggering a business action
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US7976573B2 (en) * 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7981147B2 (en) * 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2008027069A1 (en) * 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
USD613408S1 (en) 2008-02-06 2010-04-06 Tearscience, Inc. Eye treatment head gear
USD617443S1 (en) 2008-02-06 2010-06-08 Tearscience, Inc. Eye treatment goggles
USD614303S1 (en) 2008-02-06 2010-04-20 Tearscience, Inc. Eye treatment apparatus
SI2278962T1 (sl) 2008-02-21 2014-05-30 Janssen Pharmaceutica N.V. Postopki za zdravljenje dermatoloških motenj
US8343958B2 (en) 2008-02-29 2013-01-01 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists
US8008291B2 (en) * 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
US8377925B2 (en) * 2008-02-29 2013-02-19 Mimetica Pty Ltd Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
KR20120044287A (ko) * 2009-04-24 2012-05-07 얀센 파마슈티칼즈, 인코포레이티드 1,2,4-티아다이아졸 유도체를 위한 안정적인 국소 조성물
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
ES2360783B1 (es) * 2009-10-02 2012-07-04 Consejo Superior De Investigaciones Científicas (Csic) 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas
USD638128S1 (en) 2009-10-06 2011-05-17 Tearscience, Inc. Ocular device design
US8785634B2 (en) 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
WO2011143057A1 (en) 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2579873A4 (en) 2010-06-11 2013-11-27 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
RU2449997C1 (ru) * 2011-02-15 2012-05-10 Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран) 5-амино-3-(2-аминопропил)-[1,2,4]тиадиазолы
EP2628734A4 (en) * 2010-10-15 2014-04-23 Federalnoe G Bydzhetnoe Uchrezhdenie Nauki Inst Fiziol Aktivnikh Veschestv Rossiiskoi Akademii Nauk DERIVATIVES OF 5-AMINO - [1,2,4] THIADIAZOLE
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
ES2711100T3 (es) * 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
SMT202100734T1 (it) 2011-12-29 2022-03-21 Rhythm Pharmaceuticals Inc Metodo di trattamento di disturbi associati al recettore di melanocortina 4 in portatori eterozigoti
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
WO2014179356A1 (en) 2013-04-30 2014-11-06 Tear Film Innovations Llc Systems and methods for the treatment of eye conditions
JP6714589B2 (ja) 2014-10-31 2020-06-24 リポテック， エセ．ア． Ｐｓｅｕｄｏａｌｔｅｒｏｍｏｎａｓ ａｎｔａｒｃｔｉｃａ由来の細菌性細胞外生成物を含有する化粧品組成物および／または医薬組成物ならびにその使用
MX2018003983A (es) 2015-09-30 2018-11-09 Rhythm Pharmaceuticals Inc Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4.
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
CA3096055A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
CN115381955B (zh) * 2021-05-24 2024-05-17 中国科学技术大学 黑皮质素受体mc5r的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE131373C (no)
DE1670960A1 (de) * 1967-12-08 1971-02-18 Bayer Ag Verfahren zur Herstellung von salzartigen heterocyclischen Verbindungen
DD131373A1 (de) 1977-06-17 1978-06-21 Juergen Liebscher Verfahren zur herstellung von 2,3-disubstituierten 5-dialkylamino-1,2,4-thiadiazoliumsalzen
JPS6011481A (ja) 1983-06-30 1985-01-21 Nippon Soda Co Ltd １，２，４−チアジアゾ−ル系誘導体及び農園芸用殺菌剤
JPH02173165A (ja) 1988-12-27 1990-07-04 Nippon Soda Co Ltd 防汚剤
DE69708198T2 (de) * 1996-04-30 2002-03-28 Pfizer Inc., New York Muscarinische Rezeptor-Agonisten
US20020103194A1 (en) * 1997-04-30 2002-08-01 Anabella Villalobos Novel muscarinic receptor agonists
ATE372328T1 (de) * 1997-06-24 2007-09-15 Janssen Pharmaceutica Nv Angiogenese-hemmende 5-substituierte-1,2,4- thiadiazolylderivate
US6127381A (en) 1998-04-28 2000-10-03 Basu; Amaresh Isoquinoline compound melanocortin receptor ligands and methods of using same
EP1076648B1 (de) 1998-04-29 2006-07-12 MERCK PATENT GmbH Verfahren zur katalytischen herstellung von substituierten bipyridylderivaten
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
AU1324300A (en) 1998-10-26 2000-05-15 Vertex Pharmaceuticals Incorporated Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
AU2001228681A1 (en) 2000-01-28 2001-08-07 Melacure Therapeutics Ab Novel aromatic amines and amides acting on the melanocortin receptors
JP2003527444A (ja) * 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
US6728804B1 (en) 2000-10-27 2004-04-27 Emware, Inc. Remotely reprogrammable communications adapter for providing access to an electronic device
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
EP1446394B1 (en) * 2001-11-08 2006-11-02 Ortho-McNeil Pharmaceutical, Inc. Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
US7435429B2 (en) * 2002-02-07 2008-10-14 Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
SI2278962T1 (sl) 2008-02-21 2014-05-30 Janssen Pharmaceutica N.V. Postopki za zdravljenje dermatoloških motenj
KR20120044287A (ko) * 2009-04-24 2012-05-07 얀센 파마슈티칼즈, 인코포레이티드 1,2,4-티아다이아졸 유도체를 위한 안정적인 국소 조성물

Also Published As

Publication number Publication date
CN1612869A (zh) 2005-05-04
RS39604A (sr) 2006-10-27
DK1444215T3 (da) 2006-11-06
US7786311B2 (en) 2010-08-31
PT1444215E (pt) 2006-10-31
CA2466145A1 (en) 2003-05-15
US20100280079A1 (en) 2010-11-04
RU2004114208A (ru) 2005-09-10
US20030162819A1 (en) 2003-08-28
JP2005511606A (ja) 2005-04-28
ATE333449T1 (de) 2006-08-15
US20060030604A1 (en) 2006-02-09
EP1444215A1 (en) 2004-08-11
US8501791B2 (en) 2013-08-06
NZ532884A (en) 2006-06-30
RS51199B (sr) 2010-12-31
US7319107B2 (en) 2008-01-15
BR0214023A (pt) 2004-11-23
TW200303310A (en) 2003-09-01
ZA200404487B (en) 2006-08-30
IL161830A0 (en) 2005-11-20
DE60213276T2 (de) 2007-07-19
MXPA04004457A (es) 2005-06-08
EP1444215B1 (en) 2006-07-19
CY1105233T1 (el) 2010-03-03
NO328194B1 (no) 2010-01-04
US20090203751A1 (en) 2009-08-13
IL161830A (en) 2010-11-30
AR037284A1 (es) 2004-11-03
MY134994A (en) 2008-01-31
RU2323932C2 (ru) 2008-05-10
ES2268108T3 (es) 2007-03-16
SI1444215T1 (sl) 2006-12-31
AU2002340372B2 (en) 2008-12-11
TWI317358B (en) 2009-11-21
JP4491235B2 (ja) 2010-06-30
CN100422164C (zh) 2008-10-01
WO2003040118A1 (en) 2003-05-15
DE60213276D1 (de) 2006-08-31

Similar Documents

Publication Publication Date Title
NO20042372L (no) Nye 1,2,4-tiadiazolderivater som melanokortinreseptormodulatorer
DK1444215T3 (da) 1,2,4-Thiadiazoliumderivater som melanocortinreceptormodulatorer
NO20052995D0 (no) 1,5-diaryl-pyrrol-3-karboksamid-derivater, og deres anvendelse som kannabinoid reseptormodulatorer.
DK1414440T3 (da) N-phenylpyrrolguanidinderivater som melanocortinreceptorligander
DK1385825T3 (da) Substituerede 2-pyridincyclohexan-1,4-diaminderivater
NO20043022L (no) 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
NO20041567L (no) 1,8-nafthyridinderivater som antidiabetiske midler
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
NO20052761D0 (no) Spirocykliske cykloheksanderivater.
NO20035193D0 (no) Nye pyrrolderivater som farmasöytiske midler
DK1818325T3 (da) 3,4-di-substituerede cyklobuten-1,2-dioner som CXC-chemokin receptorligander
NO20015477L (no) 4,5,6,7-tetrahydroindazolderivater som antitumormidler
DK1404667T3 (da) Piperidinderivater, der er anvendelige som modulatorer af chemokinreceptoraktivitet
DK1379522T3 (da) Dihydro-benzo(b)(1,4)diazeping-2-on-derivater som MGLUR2-antagonister I
NO20034970D0 (no) Nye arylheteroalkylaminderivater
DK1637527T3 (da) Cannabinoid receptor modulator.
DK1453810T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme
DK1165547T3 (da) Substituerede benzoylpyrazoler som herbicider
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
DK1176144T3 (da) Nye N-triazolylmethyl-piperazinderivater som neurokininreceptor-antagonister
DK1523473T3 (da) Indolinderivater substitueret i position 6, deres fremstilling og anvendelse som lægemiddel.
DK1381596T3 (da) Thiazolylsubstituerede carbocykliske 1,3-dioner som pesticider
DK1406623T3 (da) Substituerede 1-phenethylpiperidinforbindelser, der bl.a. anvendes som analgetika
ITMI20020227A0 (it) Procedimento per la preparazione di alchiluree da o ,d-dimetil ditiocarbonato
NO20040913L (no) Nye 2,4-diaminotiazolderivater

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees